Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
Ting Zhou(China Pharmaceutical University), Hongchao Li(Puyang Vocational and Technical College), Lan Yang(China University of Mining and Technology), Yingdan Cao(China Pharmaceutical University), Zijing Wang(Qingdao University), Xintian Wang(China Pharmaceutical University), Aixia Ma(China Pharmaceutical University)
Cited by 28
Related Papers
The signal pathways and treatment of cytokine storm in COVID-19
|Signal Transduction and Targeted Therapy|2021|615
In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
|Frontiers in Oncology|2022|119
Spatial distribution characteristics of the COVID-19 pandemic in Beijing and its relationship with environmental factors
|The Science of The Total Environment|2020|104
Destrin Contributes to Lung Adenocarcinoma Progression by Activating Wnt/β-Catenin Signaling Pathway
|Molecular Cancer Research|2020|44
Early Gastric Cancer: Current Advances of Endoscopic Diagnosis and Treatment
|Gastroenterology Research and Practice|2016|42